EMA推荐糖尿病新药Vokanamet（SGLT-2阻断剂）上市

2014-02-27 高晓方译医学论坛网

2月20日，欧洲药品管理局(EMA)人用医药产品委员会(CHMP)推荐糖尿病治疗药物Vokanamet(活性成分为Canagliflozin和二甲双胍)授权上市。 Vokanamet适用于最大耐受剂量二甲双胍仍无法充分控制血糖水平的成人2型糖尿病患者，最大耐受剂量二甲双胍与包括胰岛素在内的其他降糖药联用仍无法充分控制血糖者，以及canagliflozin和二甲双胍单独片剂疗效不佳者。 Voka

2月20日，欧洲药品管理局(EMA)人用医药产品委员会(CHMP)推荐糖尿病治疗药物Vokanamet(活性成分为Canagliflozin和二甲双胍)授权上市。

Vokanamet适用于最大耐受剂量二甲双胍仍无法充分控制血糖水平的成人2型糖尿病患者，最大耐受剂量二甲双胍与包括胰岛素在内的其他降糖药联用仍无法充分控制血糖者，以及canagliflozin和二甲双胍单独片剂疗效不佳者。

Vokanamet活性药物为具有不同的作用机制的canagliflozin和二甲双胍。Canagliflozin通过阻断肾脏内SGLT-2蛋白降低肾脏内葡萄糖重吸收，进而降低2型糖尿病患者的血糖水平。二甲双胍则通过抑制肝脏内葡萄糖生成发挥作用。Canagliflozin与二甲双胍联用可显著改善血糖控制。

二甲双胍最常见副作用为恶心、呕吐、腹泻、腹痛和食欲减退等消化系统症状。Canagliflozin最常见副作用为低血糖(与胰岛素或磺脲类联用时)、阴道念珠菌病、尿路感染和多尿。

原始出处：

Troy Brown, RN.Canagliflozin/Metformin ( Vokanamet) Recommended by EMA for Type 2 Diabetes.Medscape February 21, 2014

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-08-05 AspirantSuo

#ANA#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-06-18 41514497@qq.com

#阻断#

30 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-11-15 一闲

#MET#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-09-20 tulenzi

#SGLT#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-07-04 fmq_28614553

#SGLT-2#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-03-25 12498ca5m83暂无昵称

#阻断剂#

19 0
[GetPortalCommentsPageByObjectIdResponse(id=1633296, encodeId=4e6f16332968f, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Tue Aug 05 09:59:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709987, encodeId=b34a1e0998731, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Jun 18 00:59:00 CST 2014, time=2014-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895711, encodeId=54541895e11e0, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Nov 15 18:59:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793766, encodeId=9b411e9376681, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Sep 20 23:59:00 CST 2014, time=2014-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081960, encodeId=b73b208196025, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Fri Jul 04 18:59:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816417, encodeId=6b3f181641ef8, content=<a href='/topic/show?id=08049e6803b' target=_blank style='color:#2F92EE;'>#阻断剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97680, encryptionId=08049e6803b, topicName=阻断剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Tue Mar 25 11:59:00 CST 2014, time=2014-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317214, encodeId=f0c8131e2142d, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Mar 01 02:59:00 CST 2014, time=2014-03-01, status=1, ipAttribution=)]
2014-03-01 fengyi812

#EMA#

31 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌科

EMA推荐糖尿病新药Vokanamet（SGLT-2阻断剂）上市

相关资讯

科室

工具

服务